Migraine induction with calcitonin gene-related peptide in patients from erenumab trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Migraine induction with calcitonin gene-related peptide in patients from erenumab trials

Published:2018-11-08 Issue:1 Volume:19 Page:
ISSN:1129-2369
Container-title:The Journal of Headache and Pain
language:en
Short-container-title:J Headache Pain

Author:

Christensen Casper Emil,Younis Samaira,Deen Marie,Khan Sabrina,Ghanizada Hashmat,Ashina Messoud

Funder

Lundbeckfonden

Rigshospitalet

Publisher

Springer Science and Business Media LLC

Subject

Anesthesiology and Pain Medicine,Neurology (clinical),General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s10194-018-0927-2.pdf

Reference28 articles.

1. Evers S, Áfra J, Frese A, Goadsby PJ, Linde M, May A et al (2009) EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol 16:968–981

2. Khan S, Olesen A, Ashina M. CGRP, a target for preventive therapy in migraine and cluster headache: systematic review of clinical data. Cephalalgia. 2017. https://doi.org/10.1177/0333102417741297

3. Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R et al (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1081–1090

4. Dodick DW, Goadsby PJ, Spierings ELH, Scherer JC, Sweeney SP, Grayzel DS (2014) Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 13:885–892

5. Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M et al (2014) Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 13:1100–1107

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic variants associated with response to anti-CGRP monoclonal antibody therapy in a chronic migraine Han Chinese population;The Journal of Headache and Pain;2024-09-12

2. A Risk-Difference Meta-Analysis for the Prophylactic Treatments of Chronic Migraine;Cureus;2024-06-16

3. Hypersensitivity to CGRP as a predictive biomarker of migraine prevention with erenumab;Cephalalgia;2024-06

4. Female-selective mechanisms promoting migraine;The Journal of Headache and Pain;2024-04-24

5. Towards precision medicine in migraine: Recent therapeutic advances and potential biomarkers to understand heterogeneity and treatment response;Pharmacology & Therapeutics;2023-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3